CEO Predicts Weight-Loss Drug Sales Will Contribute to 4% of Gerresheimer’s Annual Growth

## Gerresheimer CEO Expects Revenue Growth from Deals with Drug Makers

Gerresheimer CEO Dietmar Siemssen predicts a 4% annual revenue growth from supplying drug makers with vials, cartridges, syringes, and autoinjectors for weight loss and diabetes medications.

## Focus on GLP-1 Drugs for Revenue Boost

The company anticipates significant growth from its association with GLP-1 class drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, with sales related to these medicines expected to exceed 100 million euros this year.

## Analysts Forecast Strong Sales for Wegovy and Zepbound

Analysts project that Wegovy could generate sales of $8.6 billion this year and $12.86 billion by 2025, while Zepbound is expected to bring in around $4 billion in sales this year and $10.8 billion next year.

## Expansion Plans for GLP-1 Products

Gerresheimer is ramping up production of GLP-1 products in Germany and Mexico, with plans to use its Mexican plant as a key facility for North American markets. The company also intends to produce these products in China and the U.S. in the future.

## Positive Growth Outlook

With a revenue growth target of 5%-10% this year and 10%-15% in 2025, Gerresheimer is positioning itself for success in the growing market for weight-loss and diabetes medications. The company’s focus on GLP-1 drugs and expansion into new facilities bode well for its future growth prospects.